{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:21:04Z","timestamp":1778707264186,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004503","name":"Benha University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004503","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Systemic sclerosis (SSc) is an autoimmune disorder that causes vasculopathy and scarring, most commonly in the lungs and skin, but it can also affect other organs. Endothelial vinculin plays a critical role in angiogenesis regulation. Therefore, vinculin overexpression in SSc may give rise to anti-vinculin antibodies, which may contribute to the development of SSc vasculopathy. The current research aims to (1) determine whether anti-vinculin autoantibodies play a significant role in the diagnosis of SSc and (2) compare anti-vinculin serum levels between two scleroderma patient populations, namely, pulmonary artery hypertension (PAH)\u2013predominant and interstitial pulmonary fibrosis (IPF)\u2013predominant groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This research included 140 participants categorized into three groups: group I\u2014patients with PAH-predominant; group II\u2014patients with ILD-predominant; group III\u2014the control group. Anti-vinculin antibodies were detected in serum samples collected from all participants using ELISA. All subjects underwent high-resolution computed tomography (CT), diffusing capacity for carbon monoxide, and pulmonary function tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients in group I (PAH-predominant group, <jats:italic>N<\/jats:italic>\u2009=\u200935) were 41.3 [\u00b1\u200911.4] years old, with 80% being women. Patients in group II (ILD-predominant group, <jats:italic>N<\/jats:italic>\u2009=\u200935) were 41.0 [\u00b1\u200911.5] years old. The SSc group showed significantly higher anti-vinculin antibody levels than the control group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The PAH-predominant group demonstrated significantly higher anti-vinculin antibody levels and anti-vinculin positivity than the ILD-predominant group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Anti-vinculin antibodies in the blood appear to be diagnostic biomarkers for scleroderma. Furthermore, they shed light on some novel perspectives on the pathophysiology of specific lung fibrotic changes.<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 This study included two groups of systemic sclerosis patients (PAH-predominant group, ILD-predominant group) as well as a control group to investigate the significance of anti-vinculin antibodies in such cases.\u2022 Our results have demonstrated that anti-vinculin antibodies can play a significant role in diagnosing and monitoring systemic sclerosis disease.<\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-022-06301-0","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T08:05:06Z","timestamp":1658736306000},"page":"3401-3409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-vinculin antibodies as a novel biomarker in Egyptian patients with systemic sclerosis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-0006","authenticated-orcid":false,"given":"Noha Hosni","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman Mahmoud","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahany Mahmoud","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha Abdel Hameed","family":"El Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha Hosni","family":"Morsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al Shimaa Mohamed","family":"Sabry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nashwa Ismail","family":"Hashaad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"issue":"3","key":"6301_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5301\/jsrd.5000249","volume":"2","author":"J Varga","year":"2017","unstructured":"Varga J, Trojanowska M, Kuwana M (2017) Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord 2(3):137\u2013152","journal-title":"J Scleroderma Relat Disord"},{"key":"6301_CR2","doi-asserted-by":"crossref","unstructured":"Lleo A, Invernizzi P, Gao B, Podda M, Gershwin MEJAr. 2010 Definition of human autoimmunity\u2014autoantibodies versus autoimmune disease 9(5):A259-A66.","DOI":"10.1016\/j.autrev.2009.12.002"},{"key":"6301_CR3","doi-asserted-by":"crossref","unstructured":"Tob\u00f3n GJ, Pers J-O, Ca\u00f1as CA, Rojas-Villarraga A, Youinou P, Anaya J-MJAr. 2012 Are autoimmune diseases predictable 11(4):259\u201366.","DOI":"10.1016\/j.autrev.2011.10.004"},{"issue":"2","key":"6301_CR4","first-page":"112","volume":"25","author":"T Mendez-Rayo","year":"2018","unstructured":"Mendez-Rayo T, Ochoa-Z\u00e1rate L, Posso-Osorio I, Ortiz E, Naranjo-Escobar J (2018) Tob\u00f3n GJJRCdR. Interpretation of autoantibodies in rheumatological diseases 25(2):112\u2013125","journal-title":"Interpretation of autoantibodies in rheumatological diseases"},{"issue":"2","key":"6301_CR5","first-page":"1","volume":"5","author":"KT Ho","year":"2003","unstructured":"Ho KT (2003) Reveille JDJART. The clinical relevance of autoantibodies in scleroderma 5(2):1\u201314","journal-title":"The clinical relevance of autoantibodies in scleroderma"},{"key":"6301_CR6","unstructured":"Suliman YA, Kafaja S, Alemam M, Valera I, Morales W, Pimentel M, et al. 2016 editors. Anti-vinculin antibodies: a novel biomarker in systemic sclerosis, and its association with vascular involvement. ARTHRITIS & RHEUMATOLOGY WILEY 111 RIVER ST, HOBOKEN 07030\u20135774, NJ USA."},{"issue":"2","key":"6301_CR7","first-page":"215","volume":"224","author":"CF Deroanne","year":"1996","unstructured":"Deroanne CF, Colige AC, Nusgens BV (1996) Lapiere CMJEcr. Modulation of expression and assembly of vinculin during in vitro fibrillar collagen-induced angiogenesis and its reversal 224(2):215\u2013223","journal-title":"Modulation of expression and assembly of vinculin during in vitro fibrillar collagen-induced angiogenesis and its reversal"},{"key":"6301_CR8","doi-asserted-by":"crossref","unstructured":"Xu W, Baribault H, Adamson\u00a0EDJD (1998) Vinculin knockout results in heart and brain defects during embryonic development 125 2 327 337","DOI":"10.1242\/dev.125.2.327"},{"issue":"2","key":"6301_CR9","first-page":"749","volume":"290","author":"WH Goldmann","year":"2002","unstructured":"Goldmann WH, Ingber DEJB (2002) communications br. Intact vinculin protein is required for control of cell shape, cell mechanics, and rac-dependent lamellipodia formation 290(2):749\u2013755","journal-title":"Intact vinculin protein is required for control of cell shape, cell mechanics, and rac-dependent lamellipodia formation"},{"key":"6301_CR10","doi-asserted-by":"crossref","unstructured":"Villano M, Borghini A, Manetti M, Gabbrielli E, Rossi A, Sestini P, et al. 2013 Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells. therapeutic implications of cyclophosphamide 15(4):1\u201312","DOI":"10.1186\/ar4270"},{"issue":"6","key":"6301_CR11","first-page":"1405","volume":"39","author":"H Dib","year":"2012","unstructured":"Dib H, Tamby MC, Bussone G, Regent A, Berezn\u00e9 A, Lafine C et al (2012) Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma 39(6):1405\u20131414","journal-title":"Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma"},{"key":"6301_CR12","doi-asserted-by":"crossref","unstructured":"Suliman Y, Kafaja S, Oh SJ, Alemam M, Bagnato G, Abignano G, et al. 2021 Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts 40(6):2277\u201384.","DOI":"10.1007\/s10067-020-05479-5"},{"key":"6301_CR13","doi-asserted-by":"crossref","unstructured":"Varrica C, Dias HS, Reis C, Carvalheiro M, Sim\u00f5es SJAR. 2020 Targeted delivery in scleroderma fibrosis.:102730.","DOI":"10.1016\/j.autrev.2020.102730"},{"key":"6301_CR14","doi-asserted-by":"crossref","unstructured":"Okamura A, Matsushita T, Komuro A, Kobayashi T, Maeda S, Hamaguchi Y, et al. 2020 Adipose\u2010derived stromal\/stem cells successfully attenuate the fibrosis of scleroderma mouse models. 23(2):216-25.","DOI":"10.1111\/1756-185X.13764"},{"issue":"6","key":"6301_CR15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788\u2013824","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"6301_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/jsrd.5000231","volume":"2","author":"D Khanna","year":"2017","unstructured":"Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L et al (2017) Standardization of the modified Rodnan Skin Score for use in clinical trials of systemic sclerosis. Journal of Scleroderma and Related Disorders 2(1):11\u201318","journal-title":"Journal of Scleroderma and Related Disorders"},{"key":"6301_CR17","doi-asserted-by":"crossref","unstructured":"Talley NJ, Holtmann G, Walker MM, Burns G, Potter M, Shah A, et al. 2019 Circulating anti-cytolethal distending toxin B and anti-vinculin antibodies as biomarkers in community and healthcare populations with functional dyspepsia and irritable bowel syndrome. Clinical and translational gastroenterology 10(7).","DOI":"10.14309\/ctg.0000000000000064"},{"issue":"5","key":"6301_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126438","volume":"10","author":"M Pimentel","year":"2015","unstructured":"Pimentel M, Morales W, Rezaie A, Marsh E, Lembo A, Mirocha J et al (2015) Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS ONE 10(5):e0126438","journal-title":"PLoS ONE"},{"issue":"9","key":"6301_CR19","first-page":"453","volume":"16","author":"WH Ziegler","year":"2006","unstructured":"Ziegler WH, Liddington RC (2006) Critchley DRJTicb. The structure and regulation of vinculin 16(9):453\u2013460","journal-title":"The structure and regulation of vinculin"},{"key":"6301_CR20","doi-asserted-by":"crossref","unstructured":"Pimentel M, Morales W, Rezaie A, Marsh E, Lembo A, Mirocha J, et al. 2015 Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects Pimentel M, Morales W, Rezaie A, Marsh E, Lembo A, Mirocha J, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects 10(5):e0126438.10(5):e0126438.","DOI":"10.1371\/journal.pone.0126438"},{"issue":"3","key":"6301_CR21","first-page":"297","volume":"26","author":"F Habibzadeh","year":"2016","unstructured":"Habibzadeh F, Habibzadeh P (2016) Yadollahie MJBm. On determining the most appropriate test cut-off value: the case of tests with continuous results 26(3):297\u2013307","journal-title":"On determining the most appropriate test cut-off value: the case of tests with continuous results"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06301-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T09:16:12Z","timestamp":1665738972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06301-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6301"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06301-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"assertion":[{"value":"13 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was validated on January 18, 2022. Ethical committee approval number: RC172020. Written consents according to Helsinki declaration were taken from all patients and control subjects prior to participation in the study that was approved by the ethical committee of Faculty of Medicine, Benha University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Patients were not involved in the design, conduct, reporting, and dissemination plans of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient involvement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}